- Home
- SKYE vs ONDS Comparison
SKYE vs ONDS Comparison
Compare SKYE & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- ONDS
- Stock Information
- Founded
- SKYE 2012
- ONDS 2014
- Country
- SKYE United States
- ONDS United States
- Employees
- SKYE N/A
- ONDS N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- ONDS Telecommunications Equipment
- Sector
- SKYE Health Care
- ONDS Telecommunications
- Exchange
- SKYE Nasdaq
- ONDS Nasdaq
- Market Cap
- SKYE 80.7M
- ONDS 91.2M
- IPO Year
- SKYE N/A
- ONDS N/A
- Fundamental
- Price
- SKYE $1.44
- ONDS $0.89
- Analyst Decision
- SKYE Buy
- ONDS Strong Buy
- Analyst Count
- SKYE 6
- ONDS 2
- Target Price
- SKYE $16.60
- ONDS $3.25
- AVG Volume (30 Days)
- SKYE 1.7M
- ONDS 9.6M
- Earning Date
- SKYE 05-09-2025
- ONDS 05-14-2025
- Dividend Yield
- SKYE N/A
- ONDS N/A
- EPS Growth
- SKYE N/A
- ONDS N/A
- EPS
- SKYE N/A
- ONDS N/A
- Revenue
- SKYE N/A
- ONDS $7,192,694.00
- Revenue This Year
- SKYE N/A
- ONDS $257.28
- Revenue Next Year
- SKYE N/A
- ONDS $119.78
- P/E Ratio
- SKYE N/A
- ONDS N/A
- Revenue Growth
- SKYE N/A
- ONDS N/A
- 52 Week Low
- SKYE $1.14
- ONDS $0.54
- 52 Week High
- SKYE $17.65
- ONDS $3.40
- Technical
- Relative Strength Index (RSI)
- SKYE 40.43
- ONDS 47.78
- Support Level
- SKYE $1.26
- ONDS $0.82
- Resistance Level
- SKYE $3.73
- ONDS $0.97
- Average True Range (ATR)
- SKYE 0.34
- ONDS 0.15
- MACD
- SKYE 0.04
- ONDS 0.01
- Stochastic Oscillator
- SKYE 11.40
- ONDS 38.75
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.